Nicole S. Ng

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617.

Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617.

Journal: European urology
Published: January 28, 2025

Early neurodevelopmental outcomes of preterm infants with intraventricular haemorrhage and periventricular leukomalacia.

Early neurodevelopmental outcomes of preterm infants with intraventricular haemorrhage and periventricular leukomalacia.

Journal: Journal of paediatrics and child health
Published: February 22, 2024

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.

Journal: EBioMedicine
Published: March 13, 2023

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.

Journal: Translational andrology and urology
Published: May 10, 2021

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.

Journal: The Prostate
Published: January 18, 2021

Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.

Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.

Journal: JCO precision oncology
Published: October 23, 2020

Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.

Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.

Journal: BioTechniques
Published: July 14, 2020

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

Journal: European urology focus
Published: April 14, 2020

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.

Journal: European urology
Published: August 05, 2019

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.

Journal: European urology focus
Published: February 27, 2019

Establishing patient-reported outcome measures for the Breast Device Registry.

Establishing patient-reported outcome measures for the Breast Device Registry.

Journal: ANZ journal of surgery
Published: October 04, 2018

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.

Journal: European urology
Published: October 14, 2017
Showing 1-12 of 12

Last Updated: 09/26/2026